BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Enters Strategic Agreement for Expansion into EU Market

Brain Scientific’s (OTCQB: BRSF) Vice President of Marketing, Stuart Bernstein, has written an article for Health Care Business News titled, “COVID’s influence on neurology drives need for disposable technologies.” The piece discusses increased concern for health care and frontline workers treating emergent cases for COVID-19 patients developing neurological symptoms and conditions, as well as a critical need for testing solutions. The article reads, “Sudden onset of seizures, metabolic encephalopathy, stroke and other neurological conditions can negatively impact COVID patient outcomes and morbidity rates. Growing evidence of the commonality of neurological symptoms in COVID patients, coupled with challenges in accessibility, efficiency and sanitation of EEG administration reveals an urgent need for broader access to disposable neurological testing equipment. Disposable EEG headsets offer a solution which can be integrated easily into current standard-of-care and pair with clinical-grade EEG devices to acquire, record, transmit and display a patient’s electrical brain activity. Disposable equipment for neurological testing is well-positioned to address several challenges facing hospitals and urgent care facilities today.”

To view the full press release, visit https://ibn.fm/IHnkN

About Brain Scientific

Brain Scientific is a commercial-stage health care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances RTNova Platform with IL15 Superagonist Payload

Calidi Biotherapeutics (NYSE American: CLDI) announced the selection of IL15 superagonist (IL15-IL15Ra) as the first…

19 hours ago

BioMedNewsBreaks — Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’ 

Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical…

4 days ago

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Grants Inducement Stock Option to New CEO Eric Poma

Calidi Biotherapeutics (NYSE American: CLDI) a clinical-stage biotechnology company advancing targeted antitumor virotherapies, announced the…

4 days ago

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in Benzinga Video Highlighting 75% HyBryte™ Response Rate in FDA-Backed Skin Cancer Trial

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, is featured in a…

4 days ago

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) and AccurKardia Partner to Advance Remote ECG Monitoring

HeartBeam (NASDAQ: BEAT), a medical technology firm innovating in personalized cardiac care, has announced a…

5 days ago

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Eric Poma as CEO to Lead Next Phase of Clinical Growth

Calidi Biotherapeutics (NYSE American: CLDI) announced the appointment of Eric Poma, Ph.D., as Chief Executive…

6 days ago